Data &
Technology
Research
Reports
Report Solutions
Reports Library
Actionable
Strategies
Free
Resources
Simple Backtest Calculator
Simple Seasonality Calculator
The Kelly Criterion Calculator
Sentiment Geo Map
Public Research Reports
Free Webinar
Pricing
Company
About
Meet Our Team
In the News
Testimonials
Client Success Stories
Contact
Log inLoginSign up
< BACK TO ALL REPORTS

What to watch for in biotech

Jay Kaeppel
2022-05-11
Biotech has been one of the worst-performing sectors since topping in February 2021. Trying to pick the bottom in anything is an exercise fraught with peril. Still, no decline lasts forever. This piece highlights certain things to watch for that may alert us when better days are finally ahead for this important - but battered - sector.

Key Points

  • Biotech has been one of the hardest-hit sectors, down -59% since February 2021
  • The sector will soon be entering the most critical seasonal time of year
  • Sentiment is overdone to the bearish side

The Big Picture

The biotech sector today looks a lot like the energy sector several years ago - unwanted, unloved and in the midst of a punishing decline with seemingly no clear end in sight. And now here we are, a few years down the road and the stocks in the energy sector are about the only thing making new highs while the rest of the market declines. 

The biotech sector is oversold enough that a sizeable rebound could unfold at any time. The reality though is that trying to catch the bottom in anything is a strategy fraught with peril. The main thing to remember is that nothing is in the doghouse forever. Given the growth potential and the current fear and loathing for this sector, it could certainly follow energy's lead in the years ahead, and once again become a market leader. For now, patient opportunism appears to be in order.

Biotech seasonality

The chart below displays the annual seasonal trend for ticker IBB (iShares Biotechnology ETF). A favorable portion of the year begins at the close of Trading Day of Year (TDY) #87 and extends through TDY #179. For 2022 this period extends from the close on 5/6/2022 through 9/27/2022.

For testing purposes, we will use:

  • Ticker FBIOX (Fidelity Select Biotechnology mutual fund) from 1986 through 2000
  • Ticker IBB (iShares Biotechnology ETF) from 2001 through 2005
  • Ticker XBI (SPDR S&P Biotech ETF) since 2006

FBIOX is an actively managed index fund. IBB tracks the ICE Biotechnology Index, and XBI tracks the S&P Biotechnology Select Index. I favor XBI as it trades roughly five times as many shares and over 20 times as many options per day as ticker IBB.

The chart below displays the hypothetical cumulative % return from holding the biotech funds listed above only during the seasonally favorable period, each year since 1986.

The table below displays a summary of performance.           

Now consider the performance of biotech stocks for the rest of the year, i.e., all trading days NOT between #88 and #179.

The difference in performance becomes more apparent when we overlay both charts into one graph.

  • The favorable period (TDY #88 through TDY #179) has gained +2,075%
  • The rest of the year (TDY #1 through #87 and #180 through the end of the year) has gained +168%

Diving in based solely on seasonality is a risky play. Traders should keep an eye open for some sign of reversal in price and/or sentiment (as detailed next).

Waiting for sentiment to turn

Sentiment in the biotech sector appears to move in pretty long-term waves. Likewise, the price action in this sector is highly volatile, and prices can go to extremes very quickly, both to the upside and the downside. One of the better approaches involves waiting for sentiment to move to a long-term extreme and then reverse. 

The chart below displays occasions when the 100-day average of XBI Optix crossed above 48 for the first time in a year. You can run this test in the Backtest Engine.

The table below displays a summary of XBI performance following previous signals.

Note that the 100-day moving average is still below 40%, so this signal is likely some time away from triggering.

One more sign of an unloved sector

The screen shot below (courtesy of Charles Schwab and @LizAnnSonders) displays the number of biotech stocks (in the Nasdaq Biotechnology Index) whose stocks trade for less than the value of the cash the companies have on hand. Presently, over 20% of the stocks in the index trade for less than cash on hand.

This is not a timing indicator per se and does not mean that a turnaround is imminent.  It is however, an overwhelming indication of how unloved this sector is and offers proof that investors have thrown in the towel. This is the type of capitulation that typically sets the stage for an eventual turnaround, and offers one more reason why investors should keep an eye on the biotech sector. 

What the research tells us…

The biotech sector is entering an important time of year that has historically accounted for the bulk of annual gains. However, it enters this period in something of a freefall, so the notion of piling in based only on seasonality is fraught with peril. While jumping in while shouting "YOLO" may not be the right move, another mistake would be turning your back completely on this sector.

Any bottom could trigger a fast and furious rally with deeply oversold prices and a looming favorable seasonal period. So, investors should keep a close eye on price action. Likewise, investors should monitor XBI Optix. If the 100-day average for Optix crosses back above 48 between now and September, it could signal that better days are finally ahead. 

DATA &
TECHnologies
IndicatorEdge
‍
BackTestEdge
‍
Other Tools
‍
DataEdge API
RESEARCH
reports
Research Solution
‍
Reports Library
‍
actionable
Strategies
Trading Strategies
‍
Smart Stock Scanner
‍
FREE
RESOUrCES
Simple Backtest
Calculator
Simple Seasonality
Calculator
The Kelly Criterion
Calculator
Sentiment Geo Map
‍
Public Research Reports
‍
Free Webinar
COMPANY
‍
About
‍
Meet our Team
‍
In the News
‍
Testimonials
‍
Client Success Stories
Pricing
Bundle pricing
‍
Announcements
‍
FAQ
© 2024 Sundial Capital Research Inc. All rights reserved.
Setsail Marketing
TermsPrivacyAffiliate Program
Risk Disclosure: Futures and forex trading contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results.

Hypothetical Performance Disclosure: Hypothetical performance results have many inherent limitations, some of which are described below. No representation is being made that any account will or is likely to achieve profits or losses similar to those shown; in fact, there are frequently sharp differences between hypothetical performance results and the actual results subsequently achieved by any particular trading program. One of the limitations of hypothetical performance results is that they are generally prepared with the benefit of hindsight. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. for example, the ability to withstand losses or to adhere to a particular trading program in spite of trading losses are material points which can also adversely affect actual trading results. There are numerous other factors related to the markets in general or to the implementation of any specific trading program which cannot be fully accounted for in the preparation of hypothetical performance results and all which can adversely affect trading results.

Testimonial Disclosure: Testimonials appearing on this website may not be representative of other clients or customers and is not a guarantee of future performance or success.